| Not Yet Recruiting | Prospective Cohort Study of Pheochromocytoma/Paraganglioma NCT07516275 | Peking Union Medical College Hospital | — |
| Recruiting | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metast NCT04119024 | Anusha Kalbasi | Phase 1 |
| Withdrawn | 18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System NCT06233903 | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC) | Phase 2 |
| Recruiting | Clinical Application of Somatostatin Receptor and Norepinephrine Transporter Targeted Imaging for Diagnosis an NCT07195500 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for NCT06607692 | Fundación de investigación HM | Phase 1 / Phase 2 |
| Recruiting | Institutional Registry of Rare Diseases NCT06573723 | Hospital Italiano de Buenos Aires | — |
| Recruiting | Using the EHR to Advance Genomic Medicine Across a Diverse Health System NCT06377033 | University of Pennsylvania | N/A |
| Recruiting | Hereditary Pheochromocytoma Assessment of Tumour Immunologies NCT06444607 | Radboud University Medical Center | — |
| Recruiting | The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocyto NCT06440122 | King's College Hospital NHS Trust | — |
| Unknown | Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green NCT06155734 | Leiden University Medical Center | — |
| Not Yet Recruiting | Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study NCT04788927 | Rigshospitalet, Denmark | — |
| Recruiting | Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumo NCT05636618 | Perspective Therapeutics | Phase 1 / Phase 2 |
| Recruiting | "Receptor Radionuclide Therapy With 177Lu-DOTATOC NCT06045260 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma NCT05636540 | Heather Wachtel | EARLY_Phase 1 |
| Unknown | A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL NCT05885386 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma NCT05702944 | Seoul National University Hospital | Phase 4 |
| Active Not Recruiting | Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs NCT04711135 | Advanced Accelerator Applications | Phase 2 |
| Recruiting | Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients NCT06523582 | Universidad Nacional Autonoma de Mexico | — |
| Active Not Recruiting | Prognostic's Factors of Head and Neck Paragangliomas Evolution NCT05233878 | Hospices Civils de Lyon | — |
| Active Not Recruiting | Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare NCT05142241 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma NCT05451134 | China National Center for Cardiovascular Diseases | — |
| Unknown | Exendin PET/CT for Imaging of Paragangliomas NCT05418907 | Radboud University Medical Center | — |
| Unknown | A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL NCT05883085 | Peking Union Medical College Hospital | Phase 2 |
| Recruiting | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor NCT05069220 | Peking Union Medical College Hospital | EARLY_Phase 1 |
| Unknown | Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paragan NCT04573816 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB NCT04400474 | Grupo Espanol de Tumores Neuroendocrinos | Phase 2 |
| Withdrawn | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents NCT03923257 | Sue O'Dorisio | Phase 1 / Phase 2 |
| Terminated | A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Par NCT04187404 | Enterome | Phase 1 / Phase 2 |
| Terminated | Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROB NCT04605848 | University of Avignon | N/A |
| Withdrawn | Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Prima NCT04276597 | Excel Diagnostics and Nuclear Oncology Center | Phase 2 |
| Completed | Correlation Between Preoperative Images of PPGL and Intraoperative Hemodynamics NCT06669481 | Peking Union Medical College Hospital | — |
| Unknown | Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging NCT04017104 | British Columbia Cancer Agency | — |
| Unknown | Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease NCT04891081 | University Medical Centre Ljubljana | — |
| Recruiting | 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. NCT04081701 | Weill Medical College of Cornell University | Phase 4 |
| Active Not Recruiting | LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) NCT03946527 | Antonio Fojo | Phase 2 |
| Active Not Recruiting | Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma NCT03839498 | Columbia University | Phase 2 |
| Completed | Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma NCT05082311 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | — |
| Active Not Recruiting | DOTATOC PET/CT for Imaging NET Patients NCT03583528 | British Columbia Cancer Agency | — |
| Recruiting | Multicenter Pheochromocytoma and Paraganglioma Evaluation NCT03344016 | Felix Beuschlein | N/A |
| Recruiting | Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma NCT03206060 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Parag NCT05948137 | Asan Medical Center | — |
| Terminated | A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With NCT03165721 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Preoperative Alpha Blockade for Pheochromocytoma NCT03176693 | University of California, Los Angeles | Phase 3 |
| Active Not Recruiting | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Para NCT01941849 | University College, London | Phase 1 |
| Terminated | GA-68 DOTA-TOC of Somatostatin Positive Malignancies NCT02177773 | University of California, San Francisco | Phase 1 / Phase 2 |
| Completed | Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary NCT01967576 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors NCT01560260 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraga NCT01340794 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade N NCT01204476 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/ NCT00874614 | Molecular Insight Pharmaceuticals, Inc. | Phase 2 |
| Terminated | Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma NCT00911729 | Molecular Insight Pharmaceuticals, Inc. | — |
| Completed | Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma NCT00843037 | University Health Network, Toronto | Phase 2 |
| Completed | Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma NCT01022515 | University Hospital, Rouen | N/A |
| Completed | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma NCT00458952 | Molecular Insight Pharmaceuticals, Inc. | Phase 1 / Phase 2 |
| Completed | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoi NCT00339131 | Molecular Insight Pharmaceuticals, Inc. | Phase 1 |
| Completed | Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers NCT00188019 | University Hospital, Angers | N/A |
| Recruiting | Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions NCT03160274 | The University of Texas Health Science Center at San Antonio | — |
| Completed | A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochrom NCT01413503 | University of California, San Francisco | Phase 2 |
| Approved For Marketing | Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Parag NCT02961491 | Molecular Insight Pharmaceuticals, Inc. | — |
| Approved For Marketing | Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma NCT01377532 | University of California, San Francisco | — |
| Unknown | 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors NCT01373736 | Vancouver Coastal Health | Phase 3 |
| Available | Expanded Access Protocol Using 131I-MIBG NCT01590680 | Jubilant DraxImage Inc. | — |
| No Longer Available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma NCT01838187 | Children's Hospital Medical Center, Cincinnati | — |
| No Longer Available | 18F-FDOPA PET in Neuroendocrine Tumours NCT02431715 | British Columbia Cancer Agency | — |